New FDA guidance covers drugmakers' communications with payers, including insurance companies and formulary committees, on the safety, efficacy and cost-effectiveness of approved medical products. A second guidance document explains the agency's views on the communication of information not on drug labels, such as data from pre- or post-market studies and surveillance that might help guide patient care.
FDA issues guidance on value-based drug contracts, off-label comms
Sign up for FasterCures SmartBrief
Medical research news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.